SENTI BIOSCIENCES, INC.

Analyst Reco. Senti Biosciences, Inc.

Equities

SNTI

US81726A1007

End-of-day quote Nasdaq Other stock markets 06:00:00 2024-05-27 pm EDT			5-day change	1st Jan Change
0.3228 ^USD	-5.09%		-11.39%	-51.09%

May. 09	Senti Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 30	Senti Biosciences, Inc. Announces Publication of SENTI-202 Preclinical Data Demonstrating Potential of Logic-Gated CAR-NK Cell Therapy for the Treatment of Acute Myeloid Leukemia	CI

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Chardan Cuts Price Target on Senti Biosciences to $6 From $7, Keeps Buy Rating	23-05-11	MT
Morgan Stanley Adjusts Price Target on Senti Biosciences to $2 From $3, Keeps Equalweight Rating	23-03-24	MT
Chardan Adjusts Price Target on Senti Biosciences to $7 From $8, Keeps Buy Rating	23-03-23	MT
Chardan Adjusts Senti Biosciences' Price Target to $8 From $12, Keeps Buy Rating	23-01-30	MT
JPMorgan Initiates Coverage on Senti Biosciences With Neutral Rating	22-12-16	MT
Morgan Stanley Starts Senti Biosciences at Equalweight With $7.50 Price Target	22-10-07	MT
BofA Securities Starts Senti Biosciences at Buy With $7 Price Target	22-09-29	MT
Chardan Research Initiates Senti Biosciences With Buy Rating, $12 Price Target; Shares Climb 12% After Hours	22-09-22	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Secure and Increase the Performance of your Investments with our Team of Experts at your Side

Securing my Investments

fermer